Understanding and managing ischemic stroke.

Transient or permanent focal brain injury following acute thromboembolic occlusion develops from a complex cascade of pathophysiological events. The processes of excitotoxicity, peri-infarct depolarisation, inflammation, and apoptosis within the ischemic penumbra are proposed. While the translation of therapeutic agents from the animal models to human clinical trials have been disappointing, there remains an atmosphere of optimism as a result of the development of new diagnostic and therapeutic approaches, which include physiological, as opposed to pharmacological, intervention. This article provides an insight into the understanding of cerebral ischemia, together with current and future treatment strategies.

[1]  R. Silver,et al.  Non‐NMDA glutamate receptor occupancy and open probability at a rat cerebellar synapse with single and multiple release sites. , 1996, The Journal of physiology.

[2]  M. Fisher The Travails of Neuroprotective Drug Development forAcute Ischemic Stroke , 1998, European Neurology.

[3]  P. Deyn,et al.  Treatment of Acute Ischemic Stroke With Piracetam , 1997 .

[4]  G. Albers,et al.  Safety, Tolerability, and Pharmacokinetics of the N-Methyl-d-Aspartate Antagonist Dextrorphan in Patients With Acute Stroke , 1995 .

[5]  K. Hossmann,et al.  Neurobiology of ischemic brain damage , 1993 .

[6]  R. Rothlein,et al.  Monoclonal Antibody to the ICAM-1 Adhesion Site Reduces Neurological Damage in a Rabbit Cerebral Embolism Stroke Model , 1993, Experimental Neurology.

[7]  G. Schlaug,et al.  Enlargement of human cerebral ischemic lesion volumes measured by diffusion‐weighted magnetic resonance imaging , 1997, Annals of neurology.

[8]  C. Starmer,et al.  Na channel kinetics remain stable during perforated-patch recordings. , 1992, The American journal of physiology.

[9]  M. Chopp,et al.  Postischemic Administration of an Anti‐Mac‐1 Antibody Reduces Ischemic Cell Damage After Transient Middle Cerebral Artery Occlusion in Rats , 1994, Stroke.

[10]  L. Wilkins Practice Advisory , 1996, Neurology.

[11]  T. Olsen,et al.  Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model , 1999, BMJ.

[12]  C. Chiamulera,et al.  Activation of metabotropic receptors has a neuroprotective effect in a rodent model of focal ischaemia. , 1992, European journal of pharmacology.

[13]  E. Haley High-dose tirilazad for acute stroke (RANTTAS II). RANTTAS II Investigators. , 1998, Stroke.

[14]  David G. Norris,et al.  Evolution of Regional Changes in Apparent Diffusion Coefficient during Focal Ischemia of Rat Brain: The Relationship of Quantitative Diffusion NMR Imaging to Reduction in Cerebral Blood Flow and Metabolic Disturbances , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  P D Lyden,et al.  Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. , 1996, Circulation.

[16]  B. Siesjö,et al.  Acidosis Induced by Hypercapnia Exaggerates Ischemic Brain Damage , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  K. Lees,et al.  Duration of neuroprotective treatment for ischemic stroke. , 1998, Stroke.

[18]  P. Dorman,et al.  Recently Developed Neuroprotective Therapies for Acute Stroke , 1996 .

[19]  J. Kurhanewicz,et al.  Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. , 1990, AJNR. American journal of neuroradiology.

[20]  R. Rothlein,et al.  Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. , 1991, Stroke.

[21]  B. Davidson,et al.  Attenuation of Stroke Size in Rats Using an Adenoviral Vector to Induce Overexpression of Interleukin-1 Receptor Antagonist in Brain , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  R R Edelman,et al.  Clinical Outcome in Ischemic Stroke Predicted by Early Diffusion-Weighted and Perfusion Magnetic Resonance Imaging: A Preliminary Analysis , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  J Kucharczyk,et al.  In vivo diffusion-perfusion magnetic resonance imaging of acute cerebral ischemia. , 1991, Canadian journal of physiology and pharmacology.

[24]  S. Budd,et al.  Mechanisms of neuronal damage in brain hypoxia/ischemia: focus on the role of mitochondrial calcium accumulation. , 1998, Pharmacology & therapeutics.

[25]  S. Warach,et al.  Magnetic Resonance Imaging of Acute Stroke , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  C. Sudlow,et al.  Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. , 1997, Stroke.

[27]  B. Dardzinski,et al.  Multislice diffusion mapping for 3-D evolution of cerebral ischemia in a rat stroke model , 1995, Neurology.

[28]  W. Paschen,et al.  Multiparametric Imaging of Blood Flow and Metabolism after Middle Cerebral Artery Occlusion in Cats , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  J. Grotta Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. , 1997, Stroke.

[30]  Caroline Leigh Watkins The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997 .

[31]  G. Mies,et al.  Ischemic Thresholds of Cerebral Protein Synthesis and Energy State following Middle Cerebral Artery Occlusion in Rat , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[32]  G. Sutherland,et al.  Electron Microscopic Evidence against Apoptosis as the Mechanism of Neuronal Death in Global Ischemia , 1999, The Journal of Neuroscience.

[33]  G. D. del Zoppo,et al.  P‐Selectin and Intercellular Adhesion Molecule‐1 Expression After Focal Brain Ischemia and Reperfusion , 1994, Stroke.

[34]  A. Clark,et al.  Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia , 1997, Neuroscience Letters.

[35]  H. Diener Multinational Randomised Controlled Trial of Lubeluzole in Acute Ischaemic Stroke , 1998, Cerebrovascular Diseases.

[36]  K. Hossmann,et al.  Cortical Negative DC Deflections following Middle Cerebral Artery Occlusion and KCl-Induced Spreading Depression: Effect on Blood Flow, Tissue Oxygenation, and Electroencephalogram , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[37]  B. Siesjö,et al.  Thresholds in cerebral ischemia - the ischemic penumbra. , 1981, Stroke.

[38]  T. Wieloch,et al.  Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic drug. Evidence for chronic encephalopathic processes following ischemia. , 1996, Stroke.

[39]  G. Mies,et al.  MK-801, a glutamate antagonist, lowers flow threshold for inhibition of protein synthesis after middle cerebral artery occlusion of rat , 1993, Neuroscience Letters.

[40]  K. Hossmann Disturbances of cerebral protein synthesis and ischemic cell death. , 1993, Progress in brain research.

[41]  G. Sutherland,et al.  23Na nuclear magnetic resonance spectral changes during and after forebrain ischemia in hypoglycemic, normoglycemic, and hyperglycemic rats. , 1996, Stroke.

[42]  K. S. Lee,et al.  Intraischemic hypothermia attenuates neutrophil infiltration in the rat neocortex after focal ischemia-reperfusion injury. , 1996, Neurosurgery.

[43]  G. Hankey One Year after CAPRIE, IST and ESPS 2 , 1998, Cerebrovascular Diseases.

[44]  Jin-Moo Lee,et al.  The changing landscape of ischaemic brain injury mechanisms , 1999, Nature.

[45]  L. Squire,et al.  Enduring memory impairment in monkeys after ischemic damage to the hippocampus , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[46]  Davis Dr Effects of alcohol on the fetus. , 1978, The New England journal of medicine.

[47]  K. Lees,et al.  Does neuroprotection improve stroke outcome? , 1998, The Lancet.

[48]  M. Miller,et al.  Polyethylene glycol-conjugated superoxide dismutase in focal cerebral ischemia-reperfusion. , 1993, The American journal of physiology.

[49]  N. Wahlgren,et al.  The clomethiazole acute stroke study (CLASS): efficacy results in 545 patients classified as total anterior circulation syndrome (TACS). , 1999, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[50]  R R Edelman,et al.  Time course of the apparent diffusion coefficient (ADC) abnormality in human stroke , 1997, Neurology.

[51]  B. Siesjö,et al.  Penumbral Tissues Salvaged by Reperfusion Following Middle Cerebral Artery Occlusion in Rats , 1992, Stroke.

[52]  C. Iadecola,et al.  Caspase inhibitors reduce neuronal injury after focal but not global cerebral ischemia in rats. , 2000, Stroke.

[53]  M E Moseley,et al.  High-Speed MR Imaging of Ischemic Brain Injury following Stenosis of the Middle Cerebral Artery , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[54]  N. Rothwell,et al.  Neuroprotective Effects of Human Recombinant Interleukin-1 Receptor Antagonist in Focal Cerebral Ischaemia in the Rat , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[55]  G. D. del Zoppo,et al.  Inhibition of Polymorphonuclear Leukocyte Adherence Suppresses No‐Reflow After Focal Cerebral Ischemia in Baboons , 1992, Stroke.

[56]  U. Zwiener,et al.  The distribution of normal brain water content in Wistar rats and its increase due to ischemia , 1997, Brain Research.

[57]  D. Warner,et al.  In vivo Models of Cerebral Ischemia: Effects of Parenterally Administered NMDA Receptor Glycine Site Antagonists , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[58]  K. Lees,et al.  A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. , 1995, Stroke.

[59]  B. Grøgaard,et al.  Delayed Hypoperfusion after Incomplete Forebrain Ischemia in the Rat. The Role of Polymorphonuclear Leukocytes , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[60]  J. Grotta Why do all drugs work in animals but none in stroke patients? 2 Neuroprotective therapy , 1995, Journal of internal medicine.

[61]  P. Sandercock,et al.  Low-Molecular-Weight Heparins or Heparinoids Versus Standard Unfractionated Heparin for Acute Ischemic Stroke (Cochrane Review) , 2002, Stroke.

[62]  A. Hakim The Cerebral Ischemic Penumbra , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[63]  T. L. Davis,et al.  Hyperacute stroke: evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging. , 1996, Radiology.

[64]  G. Hankey,et al.  Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations* , 1999, The Lancet.

[65]  Stroke Therapy Academic Industry Roundtable Recommendations for standards regarding preclinical neuroprotective and restorative drug development. , 1999, Stroke.

[66]  M. Fisher,et al.  Acute ischemic stroke therapy. A clinical overview. , 1997, European Neurology.

[67]  Fred Plum,et al.  Temporal profile of neuronal damage in a model of transient forebrain ischemia , 1982, Annals of neurology.

[68]  J. Davies Remacemide hydrochloride: a novel antiepileptic agent. , 1997, General pharmacology.

[69]  W. Hacke,et al.  Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I. , 1998, Stroke.

[70]  N. Wahlgren,et al.  Clomethiazole Acute Stroke Study (CLASS) Results of a Randomized, Controlled Trial of Clomethiazole Versus Placebo in 1360 Acute Stroke Patients , 1998 .

[71]  Y. Itoyama,et al.  Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. , 1995, Stroke.

[72]  Wei Li,et al.  Fast magnetic resonance diffusion‐weighted imaging of acute human stroke , 1992, Neurology.

[73]  S. Theander,et al.  Calcium, Excitotoxins, and Neuronal Death in the Brain a , 1989, Annals of the New York Academy of Sciences.

[74]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[75]  P A Wolf,et al.  Epidemiology of stroke. , 2004 .

[76]  P. Sandercock,et al.  Hospital services for patients with acute stroke in the United Kingdom: the Stroke Association Survey of consultant opinion. , 1995, Age and ageing.

[77]  C J Epstein,et al.  Manganese Superoxide Dismutase Mediates the Early Release of Mitochondrial Cytochrome C and Subsequent DNA Fragmentation after Permanent Focal Cerebral Ischemia in Mice , 1999, The Journal of Neuroscience.

[78]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[79]  B. Siewert,et al.  Acute human stroke studied by whole brain echo planar diffusion‐weighted magnetic resonance imaging , 1995, Annals of neurology.

[80]  Dwaine F. Emerich Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? , 1999 .

[81]  D. Choi,et al.  Neuroprotective Effect of Hypothermia in Cortical Cultures Exposed to Oxygen‐Glucose Deprivation or Excitatory Amino Acids , 1994, Journal of neurochemistry.

[82]  Fangyi Zhang,et al.  Delayed Reduction of Ischemic Brain Injury and Neurological Deficits in Mice Lacking the Inducible Nitric Oxide Synthase Gene , 1997, The Journal of Neuroscience.

[83]  Obrenovitch Tp The ischaemic penumbra: twenty years on. , 1995 .

[84]  R. Koehler,et al.  Monoclonal Leukocyte Antibody Does Not Decrease the Injury of Transient Focal Cerebral Ischemia in Cats , 1992, Stroke.

[85]  P. Young,et al.  Tumor necrosis factor-alpha expression in ischemic neurons. , 1994, Stroke.

[86]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[87]  G. Sutherland,et al.  Forebrain Ischemia in Diabetic and Nondiabetic BB Rats Studied With 31P Magnetic Resonance Spectroscopy , 1992, Diabetes.

[88]  M. O'Neill,et al.  Neuroprotective effects of a systemically active Group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia , 1998, Neuroreport.

[89]  M Hoehn-Berlage,et al.  Relationship between diffusion-weighted MR images, cerebral blood flow, and energy state in experimental brain infarction. , 1995, Magnetic resonance imaging.

[90]  John Whitehead,et al.  Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial , 2000, The Lancet.

[91]  J. Relton,et al.  Peripheral Administration of Interleukin-1 Receptor Antagonist Inhibits Brain Damage after Focal Cerebral Ischemia in the Rat , 1996, Experimental Neurology.

[92]  J. Povlishock,et al.  Cytochemical detection of superoxide in cerebral inflammation and ischemia in vivo. , 1992, The American journal of physiology.

[93]  M. Moskowitz,et al.  Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.

[94]  A. Buchan,et al.  Delayed Treatment with AMPA, but Not NMDA, Antagonists Reduces Neocortical Infarction , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[95]  K. Lees Cerestat and other NMDA antagonists in ischemic stroke , 1997, Neurology.

[96]  G. Zoppo Why do all drugs work in animals but none in stroke patients ? 1 Drugs promoting cerebral blood flow , 1995 .

[97]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[98]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[99]  B. J. Sussman,et al.  Thrombolysis with fibrinolysin in cerebral arterial occlusion. , 1958, Journal of the American Medical Association.

[100]  M. Kaste,et al.  The European Cooperative Acute Stroke Study (ECASS) , 1993 .

[101]  K. Muir,et al.  Neuroprotection for acute stroke: making clinical trials work. , 1999, Stroke.

[102]  D. Choi Cerebral hypoxia: some new approaches and unanswered questions , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[103]  C. Portera-Cailliau,et al.  Non‐NMDA and NMDA receptor‐mediated excitotoxic neuronal deaths in adult brain are morphologically distinct: Further evidence for an apoptosis‐necrosis continuum , 1997, The Journal of comparative neurology.

[104]  B. Palmier,et al.  Changes in oxidative stress, iNOS activity and neutrophil infiltration in severe transient focal cerebral ischemia in rats , 2002, Brain Research.

[105]  C. Portera-Cailliau,et al.  Excitotoxic neuronal death in the immature brain is an apoptosis‐necrosis morphological continuum , 1997, The Journal of comparative neurology.

[106]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[107]  K. Herholz,et al.  Effect of Piracetam on Cerebral Glucose Metabolism in Alzheimer's Disease as Measured by Positron Emission Tomography , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.